![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EPHX3 |
Gene summary for EPHX3 |
![]() |
Gene information | Species | Human | Gene symbol | EPHX3 | Gene ID | 79852 |
Gene name | epoxide hydrolase 3 | |
Gene Alias | ABHD9 | |
Cytomap | 19p13.12 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | A0A024R7F3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79852 | EPHX3 | P130T-E | Human | Esophagus | ESCC | 8.56e-12 | 3.09e-01 | 0.1676 |
79852 | EPHX3 | C38 | Human | Oral cavity | OSCC | 4.80e-05 | 4.89e-01 | 0.172 |
79852 | EPHX3 | C43 | Human | Oral cavity | OSCC | 9.85e-58 | 1.11e+00 | 0.1704 |
79852 | EPHX3 | C46 | Human | Oral cavity | OSCC | 3.76e-19 | 6.02e-01 | 0.1673 |
79852 | EPHX3 | C57 | Human | Oral cavity | OSCC | 1.20e-20 | 5.22e-01 | 0.1679 |
79852 | EPHX3 | LN46 | Human | Oral cavity | OSCC | 5.37e-17 | 7.68e-01 | 0.1666 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa05208310 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa0520830 | Oral cavity | OSCC | Chemical carcinogenesis - reactive oxygen species | 150/3704 | 223/8465 | 6.45e-13 | 1.20e-11 | 6.11e-12 | 150 |
hsa05208114 | Oral cavity | OSCC | Chemical carcinogenesis - reactive oxygen species | 150/3704 | 223/8465 | 6.45e-13 | 1.20e-11 | 6.11e-12 | 150 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EPHX3 | SNV | Missense_Mutation | rs374205173 | c.784N>A | p.Glu262Lys | p.E262K | Q9H6B9 | protein_coding | deleterious(0.02) | possibly_damaging(0.861) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EPHX3 | SNV | Missense_Mutation | novel | c.622T>C | p.Ser208Pro | p.S208P | Q9H6B9 | protein_coding | tolerated(0.06) | benign(0.334) | TCGA-E9-A226-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
EPHX3 | SNV | Missense_Mutation | novel | c.445N>C | p.Asp149His | p.D149H | Q9H6B9 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
EPHX3 | SNV | Missense_Mutation | novel | c.324N>T | p.Glu108Asp | p.E108D | Q9H6B9 | protein_coding | deleterious(0.01) | benign(0.136) | TCGA-UU-A93S-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
EPHX3 | insertion | Frame_Shift_Ins | novel | c.439_440insGGCGTGGT | p.Thr147ArgfsTer17 | p.T147Rfs*17 | Q9H6B9 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
EPHX3 | insertion | Nonsense_Mutation | novel | c.437_438insAAATAAAGTATGGC | p.Tyr146Ter | p.Y146* | Q9H6B9 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
EPHX3 | SNV | Missense_Mutation | c.182N>A | p.Ser61Asn | p.S61N | Q9H6B9 | protein_coding | tolerated(0.42) | benign(0.001) | TCGA-LP-A5U2-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
EPHX3 | SNV | Missense_Mutation | novel | c.720N>T | p.Gln240His | p.Q240H | Q9H6B9 | protein_coding | tolerated(0.12) | benign(0.14) | TCGA-RA-A741-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
EPHX3 | insertion | Frame_Shift_Ins | novel | c.356_357insAGTAG | p.Phe120ValfsTer43 | p.F120Vfs*43 | Q9H6B9 | protein_coding | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
EPHX3 | SNV | Missense_Mutation | c.256C>A | p.Arg86Ser | p.R86S | Q9H6B9 | protein_coding | deleterious(0) | benign(0.115) | TCGA-CM-6166-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |